Items of the Montgomery-Åsberg Depression Rating Scale Associated With Response to Paroxetine Treatment in Patients With Major Depressive Disorder
- PMID: 27171569
- DOI: 10.1097/WNF.0000000000000146
Items of the Montgomery-Åsberg Depression Rating Scale Associated With Response to Paroxetine Treatment in Patients With Major Depressive Disorder
Abstract
Objectives: In the present study, we investigated the association between the severity of each symptom evaluated by the Montgomery-Åsberg Depression Rating Scale (MADRS) at baseline and responsiveness to treatment in patients with major depressive disorder (MDD) to identify the items that predict treatment response.
Methods: The patients received a diagnosis of MDD if they had a score greater than 20 points on the MADRS. Following admission, 120 patients were enrolled in the study, and 89 patients completed the study. For the first week, a 20-mg/d dose of paroxetine was administered; thereafter, the dose was increased to 40 mg/d. The MADRS was applied at baseline and after 1, 2, 4, and 6 weeks. We defined responders as patients with improvements in their MADRS scores of more than 50% after 6 weeks of treatment. A multiple regression analysis of MADRS scores at 6 weeks was performed to identify patients who responded to treatment.
Results: There was a significant difference between responders and nonresponders in the reported sadness (RS) score for all MADRS items. In the multiple logistic regression analysis, only the RS and concentration difficulties (C) scores showed a significant association with treatment response. Based on the results of χ tests, RS score cutoff values of 2/3 and 3/4 revealed significant differences in the responder rate. None of the cutoff values for the C score revealed significant differences.
Conclusions: The RS score was significantly associated with responsiveness to paroxetine treatment for MDD, with higher RS scores predicting poor responses to treatment.
Similar articles
-
Effects of age on paroxetine efficacy in patients with major depressive disorder who do not exhibit an early response to treatment.Clin Neuropharmacol. 2015 Jan-Feb;38(1):6-10. doi: 10.1097/WNF.0000000000000058. Clin Neuropharmacol. 2015. PMID: 25580920
-
A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.Curr Med Res Opin. 2006 Jul;22(7):1331-41. doi: 10.1185/030079906X115513. Curr Med Res Opin. 2006. PMID: 16834832 Clinical Trial.
-
An investigation of temperament and character inventory items for predicting the response to paroxetine treatment in patients with major depressive disorder.J Affect Disord. 2014 Aug;165:109-13. doi: 10.1016/j.jad.2014.04.076. Epub 2014 May 4. J Affect Disord. 2014. PMID: 24882186
-
Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials.J Affect Disord. 2011 Jul;132(1-2):14-25. doi: 10.1016/j.jad.2010.08.018. Epub 2010 Sep 21. J Affect Disord. 2011. PMID: 20863574 Review.
-
Stereotactic Radiofrequency Ablation for Treatment-Refractory Depression: A Systematic Review and Meta-Analysis.Brain Sci. 2022 Oct 12;12(10):1379. doi: 10.3390/brainsci12101379. Brain Sci. 2022. PMID: 36291313 Free PMC article. Review.
Cited by
-
Paroxetine combined with olanzapine in the treatment of schizophrenia.Pak J Med Sci. 2020 Mar-Apr;36(3):516-520. doi: 10.12669/pjms.36.3.846. Pak J Med Sci. 2020. PMID: 32292463 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources